Description
P18 Ibrutinib, the first available BTK inhibitor: single centre experience
Article: P18 Ibrutinib, the first available BTK inhibitor: single centre experience
€3.03
Related products
-
Article: Highlights in digestive oncology
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart
